{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:05:40Z","timestamp":1777543540234,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"am","delay-in-days":285,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.fjurol.2024.102838","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T17:33:27Z","timestamp":1733247207000},"page":"102838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["High-risk non-muscle invasive bladder cancer: Outcomes of patients who cannot benefit from standard of care"],"prefix":"10.1016","volume":"35","author":[{"given":"Thomas","family":"Palkowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Thiery-Vuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Kleinclauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-9538","authenticated-orcid":false,"given":"Alexandre","family":"Frontczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2024.102838_bib0135","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0140","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.purol.2022.08.006","article-title":"Cancer Committee guidelines - update 2022-2024: non-muscle-invasive bladder cancer (NMIBC)","volume":"32","author":"Neuzillet","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0145","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0150","article-title":"EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)","author":"Gontero","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.purol.2022.01.001","article-title":"Recommandations des Comit\u00e9s de canc\u00e9rologie (CC-AFU) et d\u2019infectiologie (CI-AFU) de l\u2019Association fran\u00e7aise d\u2019urologie pour la prise en charge effets ind\u00e9sirables et complications du BCG","volume":"32","author":"Audenet","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/UA.UA_115_17","article-title":"Prognostic impact of Bacillus Calmette-Gu\u00e9rin interruption at the time of induction and consolidation","volume":"9","author":"Alhogbani","year":"2017","journal-title":"Urol Ann"},{"key":"10.1016\/j.fjurol.2024.102838_bib0165","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejso.2013.11.003","article-title":"Transuretral resection of the bladder (TURB): analysis of complications using a modified Clavien system in an Italian real life cohort","volume":"40","author":"De Nunzio","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0170","first-page":"40.e9","article-title":"Comparison of standard vs. palliative management for bladder cancer in patients older than 85 years: multicenter study of 317 de novo tumors","volume":"38","author":"Carrion","year":"2020","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.fjurol.2024.102838_bib0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of Bacillus Calmette-Gu\u00e9rin Connaught Strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102838_bib0180","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-019-01581-0","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0185","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000496802","article-title":"Comparison of outcomes between standard and palliative management for high grade non-muscle invasive bladder cancer in patients older than 85 years","volume":"102","author":"Carrion","year":"2019","journal-title":"Urol Int"},{"key":"10.1016\/j.fjurol.2024.102838_bib0190","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1166-7087(20)30751-X","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019AFU\u2013actualisation 2020-2022\u00a0: tumeurs de la vessie","volume":"30","author":"Roupr\u00eat","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0195","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1166-7087(16)30704-7","article-title":"CCAFU French national guidelines 2016-2018 on bladder cancer","volume":"27","author":"Roupr\u00eat","year":"2016","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0200","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0205","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0210","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/iju.14372","article-title":"Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer","volume":"27","author":"Taoka","year":"2020","journal-title":"Int J Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0215","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/JU.0000000000002678","article-title":"All high-grade Ta tumors should be classified as high risk: Bacillus Calmette-Gu\u00e9rin response in high-grade Ta tumors","volume":"208","author":"Bree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0220","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.13354","article-title":"The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/Grade 3 bladder cancer treated with bacille Calmette-Gu\u00e9rin","volume":"118","author":"Gontero","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102838_bib0225","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eururo.2010.03.007","article-title":"Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial","volume":"58","author":"Divrik","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.purol.2019.11.006","article-title":"Int\u00e9r\u00eat de la r\u00e9section compl\u00e9mentaire (ou \u00ab\u00a0second look\u00a0\u00bb) pour les carcinomes uroth\u00e9liaux de vessie class\u00e9s pTa haut grade","volume":"30","author":"Branchu","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0235","first-page":"287","article-title":"Is there a role for second transurethral resection in pTa high-grade urothelial bladder cancer?","volume":"71","author":"Dangi","year":"2018","journal-title":"Cent Eur J Uro"},{"key":"10.1016\/j.fjurol.2024.102838_bib0240","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0245","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.urolonc.2019.08.010","article-title":"Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?","volume":"38","author":"Soria","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0250","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.juro.2007.11.079","article-title":"Late age (85 years or older) peak incidence of bladder cancer","volume":"179","author":"Schultzel","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0255","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.urolonc.2009.07.020","article-title":"Bladder cancer in the elderly","volume":"27","author":"Shariat","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102838_bib0260","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bju.14419","article-title":"Bladder cancer in nonagenarians: a multicentre study of 123 patients","volume":"122","author":"Eredics","year":"2018","journal-title":"BJU Int"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024003061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024003061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:57:24Z","timestamp":1745233044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393024003061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2950393024003061"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102838","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-risk non-muscle invasive bladder cancer: Outcomes of patients who cannot benefit from standard of care","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102838"}}